MolecularMatch Names Kevin Krenitsky, MD to Board of Directors

HOUSTON, TX (PRWEB) May 18, 2015

MolecularMatch, Inc., a molecular information and technology company, today announced the appointment of Kevin Krenitsky, MD to the board of directors.

Dr. Krenitsky has spent a great part of his career driving commercial success at life science companies. Dr. Krenitsky was recently named president of OpGen, Inc., a molecular testing and bioinformatics company. Previously he was with Foundation Medicine, Inc., a leading diagnostic laboratory and informatics company. There he held multiple roles including Chief Operating Officer, Chief Commercial Officer & SVP of International Strategy.

Kevin has a deep understanding of the molecular diagnostic field. We are thrilled to have him join our board, stated Kevin Coker, CEO of MolecularMatch. During his tenure at Foundation, he was instrumental in taking the company from a start-up to a $ 1 billion IPO in two years. I worked with Kevin closely while I was at US Oncology / McKesson and got to know him not only as a thoughtful leader, but as someone with a vision and the ability to execute a plan.

Dr. Krenitsky will be influential as MolecularMatch looks to expand its commercial offering and customer base. In March, MolecularMatch launched a new website and search engine for oncologists. Later this year they will be launching their first commercial product – a technology platform that will bring unparalleled ability of speed and scale to deliver molecular interpretation.

“I am very excited to be joining the MolecularMatch Board of Directors. The software was created by an MD Anderson physician, for physicians. They are focused on putting physicians at the center of their technology. I was drawn not only to their mission but their innovative technology, said Krenitsky. MolecularMatch has a platform that will keep pace with the increase in demand and complexity facing this field. I look forward to actively innovating with their team.

About MolecularMatch, Inc.

MolecularMatch, Inc. ( makes personalized medicine a reality. MolecularMatch is optimized for cancer patients in the United States. The core service is a web-based tool intended to match a patients genetic information from their disease to an appropriate therapy. The tool creates evidence-based treatment suggestions containing: 1) FDA-approved therapies, 2) experimental therapies, and 3) appropriate clinical trials. Information provided by MolecularMatch is for informational purposes and should not take the place of information given by a physician or healthcare provider.

Media Contact

Jennifer Horspool



Leave a Reply